Merck Serono, Kadimastem in MS deal

Merck Serono partnered with Kadimastem Ltd. (Ness Ziona, Israel) to use the Israeli company's drug-screening technology to discover oral therapies for multiple sclerosis. Under the five-year deal, Kadimastem will use its pluripotent stem cell technology to screen for compounds from Merck that stimulate myelin repair. Merck Serono is a unit of Merck KGaA (Xetra:MRK). ...